Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Cash from Investing Activities of -$27000.0 for Q1 2026, up 97.49% year-over-year from -$13671.7 in Q1 2025, and up 94.51% quarter-over-quarter from -$492000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Cash from Investing Activities data on file, last reported at -$27000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$27000.0, up 97.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.4 million (up 52.19% YoY), and the FY2025 annual result was -$5.5 million, up 37.61% from the prior year.
- Cash from Investing Activities climbed to -$27000.0 in Q1 2026 per RNAC's latest filing, from -$492000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $28.1 million in Q1 2023 and troughed at -$29.9 million in Q3 2022.
- A 5-year average of $336500.0 and a median of -$423000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 194.65% in 2023, then tumbled 13125.0% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $5.5 million in 2022, then grew by 18.36% to $6.5 million in 2023, then sank by 105.45% to -$354000.0 in 2024, then plunged by 38.98% to -$492000.0 in 2025, then surged by 94.51% to -$27000.0 in 2026.
- Business Quant data shows RNAC's Cash from Investing Activities at -$27000.0 in Q1 2026, -$492000.0 in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | -492,000.00 |
| Dec 31, 2025 | -492,000.00 |
| Sep 30, 2025 | -1.29 Mn |
| Sep 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Mar 31, 2025 | -1.08 Mn |
| Mar 31, 2025 | -1.08 Mn |
| Dec 31, 2024 | -354,000.00 |
| Dec 31, 2024 | -354,000.00 |
| Sep 30, 2024 | -6.20 Mn |
| Sep 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -602,000.00 |
| Mar 31, 2024 | -602,000.00 |
| Dec 31, 2023 | 6.50 Mn |
| Dec 31, 2023 | 6.50 Mn |